Financial Data and Key Metrics Changes - In 2025, the company reported revenues of $1.9 billion, primarily driven by sales of its COVID vaccine Spikevax and mNEXSPIKE [5][11] - Operating expenses decreased by $2.2 billion, or 30%, compared to the previous year [5] - The net loss for the year was $2.8 billion, an improvement from a net loss of $3.6 billion in 2024 [14] - The company ended the year with $8.1 billion in cash and investments, down from $9.5 billion at the end of 2024 [14][15] Business Line Data and Key Metrics Changes - The company had three products on the market in 2025: Spikevax, mNEXSPIKE, and mRESVIA, with mNEXSPIKE quickly becoming the leading product in the U.S. [7] - For the fourth quarter, total revenue was $700 million, with $300 million from the U.S. and $400 million from international markets [11] - The U.S. revenue totaled $1.2 billion for the full year, while international revenue was $700 million [11] Market Data and Key Metrics Changes - In the U.S., despite a decline in overall COVID market demand, the company maintained strong market share in the retail channel, supported by the successful launch of mNEXSPIKE [12] - Internationally, operational performance and vaccination rates exceeded expectations, contributing to revenue growth [11] Company Strategy and Development Direction - The company aims for total revenue growth of up to 10% in 2026, primarily driven by international markets and local manufacturing agreements in the U.K. and Australia [15][16] - The company plans to launch mNEXSPIKE and its combination flu-COVID vaccine in Europe by the 2027 winter season, expanding its market share [20][21] - Strategic partnerships in Latin America and Asia Pacific are expected to drive growth, alongside the anticipated approval of its flu vaccine in multiple countries [21][27] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the FDA's refusal to file letter regarding the flu program, highlighting the challenges posed by regulatory uncertainty [6] - The company remains optimistic about its pipeline and expects continued clinical momentum, particularly in oncology and infectious disease programs [32][33] Other Important Information - The company has completed enrollment in several late-stage cancer studies and anticipates data readouts in 2026 [9][28] - A new Chief Development Officer, Dr. David Berman, will join the company, bringing extensive experience in clinical-stage immunotherapies [10] Q&A Session Summary Question: Implications of flu RTF on cash flow break-even guidance and INT program timing - Management noted that the flu filing is under review in Europe, Canada, and Australia, with the U.S. refile pending a Type A meeting with the FDA [36][37] - The INT program for adjuvant melanoma is event-driven, with data expected this year [42] Question: Thoughts on flu and COVID combination vaccine refile - The company is awaiting feedback from the FDA on what is needed to refile the mRNA-1010 program, with a comprehensive data set already submitted [45][47] - The phase III study for mRNA-1010 showed superior efficacy compared to standard vaccines [49][50] Question: European COVID vaccination market and flu vaccine strain selection - The company anticipates a larger market share in Europe, with mNEXSPIKE expected to be competitive [56][58] - Discussions on better strain matching for flu vaccines are ongoing, with strong support from international regulators [59][61]

Core Viewpoint - Intensity Therapeutics, Inc. announced a 1-for-25 reverse stock split to increase the per share trading price and regain compliance with Nasdaq's minimum bid price requirement [1] Company Overview - Intensity Therapeutics is a late-stage clinical biotechnology company focused on developing novel intratumoral cancer therapies using proprietary non-covalent conjugation technology [1] - The company’s lead product candidate, INT230-6, is designed for direct intratumoral injection and combines two potent anti-cancer agents, cisplatin and vinblastine sulfate, with a diffusion enhancer [1] Reverse Stock Split Details - The reverse stock split will take effect on February 18, 2026, with trading on a split-adjusted basis starting February 19, 2026 [1] - The number of outstanding shares will decrease from approximately 63,346,579 to about 2,533,863 shares [1] - No fractional shares will be issued; stockholders will receive cash payments for any fractional shares [1] Clinical Trials and Product Development - INT230-6 has shown the ability to kill tumors and elicit an immune response within days of injection, representing a potential shift in cancer treatment paradigms [1] - The company has completed two clinical studies with over 200 patients, including a Phase 1/2 study in metastatic cancers and a Phase 2 randomized control trial in locally advanced breast cancer [1] - A Phase 3 trial in soft tissue sarcoma and a Phase 2 study in collaboration with the Swiss Cancer Group are also underway [1]

Core Insights - Viking Therapeutics, Inc. (VKTX) is experiencing a recovery in its stock price, driven by positive market sentiments [1] - The analysis emphasizes the importance of identifying attractive risk/reward opportunities that can outperform the S&P 500 [1] - The focus is on stocks with strong growth potential and those that are undervalued, presenting significant upside recovery possibilities [1] Group 1 - The company has been recognized for its ability to identify high-potential investment opportunities across various sectors [1] - The investment strategy combines price action analysis with fundamental analysis to generate alpha consistently [1] - The approach avoids overhyped stocks while capitalizing on beaten-down stocks with recovery potential [1] Group 2 - The investing group Ultimate Growth Investing specializes in growth stocks with solid fundamentals and robust buying momentum [1] - The main ideas revolve around contrarian plays that can lead to appealing turnaround opportunities [1] - The analyst has no current positions in the mentioned companies and expresses independent opinions [1]

Core Insights - Viking Therapeutics, Inc. (VKTX) is experiencing a recovery in stock performance, driven by market sentiments that suggest a potential upside [1] - The analysis emphasizes the importance of identifying attractive risk/reward opportunities that can outperform the S&P 500 [1] Group 1: Market Sentiment and Stock Performance - The stock of Viking Therapeutics has shown signs of recovery, indicating positive market sentiment [1] - There is a belief that the recent wave of selling presents an opportunity for investors [1] Group 2: Investment Strategy - The investment approach focuses on combining price action analysis with fundamental analysis to identify high-potential stocks [1] - The strategy includes avoiding overhyped stocks while targeting those that are undervalued with significant recovery potential [1] Group 3: Analyst Recognition and Expertise - The analyst has been recognized as a Top Analyst by TipRanks and Seeking Alpha, indicating credibility in stock analysis [1] - The investment group Ultimate Growth Investing specializes in identifying growth stocks with solid fundamentals and turnaround potential [1]

Core Insights - MetaVia Inc. has developed a robust global patent portfolio for its lead asset DA-1726, which is a dual agonist for treating obesity and metabolic disorders, with protection extending to 2041 [1] - The company has 39 granted and pending patents in the U.S. and internationally, covering the unique peptide structure and therapeutic use of DA-1726 [1] - Recent clinical data indicate that DA-1726 at a 48 mg dose resulted in approximately 9% weight loss, significant waist size reduction, and improvements in blood sugar levels, all with a favorable safety profile [1] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases [1] - The company is developing DA-1726 for obesity treatment and vanoglipel (DA-1241) for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [1] - DA-1726 is designed to be administered once weekly subcutaneously and functions as a dual agonist of GLP-1 and glucagon receptors [1] Product Development - DA-1726 has shown best-in-class potential in pre-clinical studies, outperforming semaglutide in weight loss while allowing for greater food intake [1] - The Phase 1 multiple ascending dose trial demonstrated significant potential for weight loss, glucose control, and waist circumference reduction [1] - Planned 16-week titration studies to 48 mg and 64 mg are expected to yield results in Q4 2026, reflecting confidence in the therapy's tolerability [1]

Core Insights - Moderna reported Q4 revenue of $678 million, surpassing estimates of $663 million, while total sales fell 29% year-over-year due to declining COVID vaccine demand [1] - The company significantly reduced annual operating expenses by $2.2 billion, exceeding cost-reduction targets, and narrowed its quarterly loss by 26% year-over-year [1] - The FDA declined to review Moderna's flu vaccine application, delaying diversification efforts beyond COVID vaccines, which negatively impacted share prices [1] Financial Performance - Q4 revenue was $678 million, compared to a loss of $2.11 per share, better than the expected loss of $2.64 [1] - Full-year 2025 revenue was $1.94 billion, down 40% from $3.24 billion in 2024, with a reduced net loss of $2.82 billion from $3.56 billion [1] - The company held $8.1 billion in cash and investments at year-end 2025, after drawing $600 million from its credit facility [2] Cost Management - R&D spending in Q4 decreased by 31% to $775 million as the company wound down Phase 3 respiratory programs [1] - The operational efficiency achieved through cost discipline is highlighted as a significant achievement for the quarter [1] Market Dynamics - International product sales reached $381 million, surpassing U.S. sales of $264 million, indicating a strategic shift towards markets with better vaccine adoption [1] - The company secured international partnerships, including a five-year agreement with Mexico for up to 10 million COVID-19 vaccine doses [1] Regulatory Challenges - The FDA issued a Refusal-to-File letter for Moderna's flu vaccine, delaying its U.S. market entry but maintaining potential revenue from international markets [1] - Despite the setback, the company maintains that it will not impact its 2026 financial guidance [1] Future Outlook - Management projects revenue growth of up to 10% in 2026, estimating approximately $2.13 billion in sales with a balanced split between U.S. and international markets [1] - The company is advancing multiple oncology programs and rare disease therapeutics, with significant data readouts expected in 2026 [2] Valuation Considerations - Moderna's market capitalization stands at $15.67 billion, trading at 7x trailing sales despite ongoing losses [2] - Analysts have a consensus price target of $38.40, with mixed ratings reflecting the company's transition challenges [2]

Core Insights - Medicenna Therapeutics is advancing its clinical pipeline with promising data for MDNA11 and MDNA113, targeting various cancers and autoimmune diseases [2][3][21] Clinical Data and Trials - Updated clinical data from the ABILITY-1 trial shows MDNA11 achieving an objective response rate (ORR) of 36% in monotherapy and 43% when combined with pembrolizumab in patients treated as second or third-line therapy [4][5] - The ABILITY-1 study has expanded to include patients with non-small cell lung cancer (NSCLC) and secondary resistance to checkpoint therapy, addressing a significant unmet need in cancer treatment [4][6] - The NEO-CYT trial will evaluate MDNA11 in combination with nivolumab for high-risk melanoma, with patient enrollment expected to start in H1 2026 and interim data anticipated in H2 2026 [8][10] Product Development - MDNA113, a bifunctional anti-PD-1–IL-2 superkine, is progressing through IND-enabling studies, with plans to submit an IND in H2 2026 after demonstrating a favorable safety profile in non-human primates [3][14] - Bizaxofusp (formerly MDNA55) has shown a significant increase in median overall survival for recurrent glioblastoma patients, with a median overall survival of 13.6 months compared to the standard of care of 7 months [14] Financial Overview - As of December 31, 2025, Medicenna reported cash and cash equivalents of $10.6 million, expected to fund operations into Q3 2026 [16] - The company reported total operating costs of $5.6 million for the quarter, an increase from $5.1 million in the same period the previous year, primarily due to higher R&D expenditures [17][19] - The net loss for the quarter was $4.4 million, a decrease from $5.2 million in the prior year, attributed to an increase in the gain on the fair value of derivative warrant liability [18]

Core Insights - Medicenna Therapeutics is advancing its clinical pipeline with promising data for MDNA11 and MDNA113, aiming for significant milestones in 2026 [2][3] Clinical Data and Trials - The ABILITY-1 trial for MDNA11 shows an objective response rate (ORR) of 36% in monotherapy and 43% when combined with pembrolizumab, with a disease control rate (DCR) of 86% and 72% respectively [3][4] - A new expansion cohort in the ABILITY-1 study will treat patients with non-small cell lung cancer (NSCLC) and secondary resistance to checkpoint therapy [3][5] - The NEO-CYT trial will evaluate MDNA11 in combination with nivolumab for melanoma, with patient enrollment expected to start in H1 2026 and interim data anticipated in H2 2026 [7][9] Product Development - MDNA113, a bifunctional anti-PD-1–IL-2 superkine, is progressing through IND-enabling studies, with plans to submit an IND in H2 2026 [2][12] - Bizaxofusp (formerly MDNA55) has shown a median overall survival (mOS) of 13.6 months in a Phase 2b trial for recurrent glioblastoma, compared to the standard mOS of 7 months [12] Financial Overview - As of December 31, 2025, Medicenna reported cash and cash equivalents of $10.6 million, expected to fund operations into Q3 2026 [14] - The company reported total operating costs of $5.6 million for the quarter, an increase from $5.1 million in the same period the previous year, primarily due to higher R&D expenditures [15][17] - The net loss for the quarter was $4.4 million, a decrease from $5.2 million in the prior year, attributed to a gain on the fair value of derivative warrant liability [16]

Fourth Quarter 2025 Financial Results This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's 2026 financial framework, including up to ten percent revenue growth and further cost reductions in 2026; Moderna's year-end cash balance; Moderna's multi-year revenue growth strategy; Moderna's expectations regarding durable growth supported by strategic agreements and global approvals; M ...

Core Insights - Moderna reported a fourth-quarter loss of $2.11 per share, indicating financial challenges for the company [1] - The company's revenue for the quarter was $678 million, reflecting a significant decline compared to previous periods [1] Financial Performance - The reported loss of $2.11 per share highlights the company's struggle to maintain profitability [1] - Revenue of $678 million suggests a downturn in sales, which may impact future growth prospects [1]